Overview

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Status:
Not yet recruiting
Trial end date:
2029-01-23
Target enrollment:
Participant gender:
Summary
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals